IMMUNORNASE FUSIONS - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 343

169. Newton DL, Pearson JW, Xue Y, Smith MR, Fogler WE,
Mikulski SM, et al. (1996) Anti-tumor ribonuclease, com-
bined with or conjugated to monoclonal antibody MRK16,
overcomes multidrug resistance to vincrinstine in vitro and in
vivo. Int. J. Oncol. 8, 1095-1104.
170. Rybak SM. (2008) Antibody-Onconase 1 conjugates: cyto-
toxicity and intracellular routing. Curr. Pharm. Biotechnol. 9,
226-230.
171. Arai R, Ueda H, Kitayama A, Kamiya N, Nagamune T.
(2001) Design of the linkers which effectively separate
domains of a bifunctional fusion protein. Protein Eng. 14,
529-532.
172. Keller J, Heisler I, Tauber R, Fuchs H. (2001) Development of
a novel molecular adapter for the optimization of immuno-
toxins. Control Release 74, 259-261.
173. Chen X, Bai Y, Zaro JL, ShenWC. (2010) Design of an in vivo
cleavable disulfide linker in recombinant fusion proteins.
Biotechniques 49, 513-518.
174. Buchner J, Pastan I, Brinkmann U. (1992) A method for
increasing the yield of properly folded recombinant
fusion proteins: single-chain immunotoxins from rena-
turation of bacterial

177. Hetzel C, Bachran C, Tur MK, Fuchs H, Stocker M. (2009)
Improved immunotoxins with novel functional elements.
Curr. Pharm. Des. 15, 2700-2711.
178. Rybak SM, Newton DL. (2007) Immunotoxins and beyond:
targeted RNases. In: Dubel S. (Ed), Handbook of Therapeutic
Antibodies. Wiley-VCH, Weinheim, pp. 379-410.
179. Newton DL, Stockwin LH, Rybak SM. (2009) Anti-CD22
Onconase 1 : preparation and characterization. Methods Biol.
525, 425-443.
180. Saxena SK. inventor; Alfacell Corporation, assignee. US
patent 6,175,003B1.(2001) January 16.
181. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J,
Griffiths AD, Winter G. (1991) By-passing immunization.
Human antibodies from V-gene libraries displayed on phage.
J. Mol. Biol. 222, 581-597.
182. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope
AR, Earnshaw JC, et al. (1996) Human antibodies with sub-
nanomolar affinities isolated from a large non-immunized
phage display library. Nat. Biotechnol. 14, 309-314.
183. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC,
Henderikx P, et al. (1999) A large non-immunized human Fab
fragment phage library that permits rapid isolation and kinetic
analysis of high affinity antibodies. J. Biol. Chem. 274,
18218-18230.
184. Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD.
(2000) Selection of tumor-specific internalizing human anti-
bodies from phage libraries. J. Mol. Biol. 301, 1149-1161.
185. O'Connell D, Becerril B, Roy-Burman A, Daws M, Marks
JD. (2002) Phage versus phagemid libraries for generation of
human monoclonal antibodies. J. Mol. Biol. 321, 49-56.

inclusion bodies. Anal. Biochem.

205, 263-270.
175. Schirmann T, Wezler X, Dubel S. Human antibody RNase
fusion proteins targeting CD30 þ lymphoma. Proceedings of
the 8th RNase Congress; 2010 October 20-22; Naples, Italy.
23.
176. Kreitman RJ. (2009) Recombinant immunotoxins for the
treatment of chemoresistant hematologic malignancies.
Curr. Pharm. Des. 15, 2652-2664.